(:SBPH)

Nov 20, 2020 11:59 am ET
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform the lives of patients with cancer through the development of innovative tetravalent mAb2 bispecific antibodies, today announced the completion of its business combination with Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH through November 20, 2020), following Spring Bank stockholder approval on November 19, 2020.
Nov 20, 2020 11:53 am ET
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline.
Nov 19, 2020 05:00 pm ET
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier...
Nov 07, 2020 07:33 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – MVC, WPX, PTI, SBPH
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings...
Nov 06, 2020 05:01 pm ET
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the...
Nov 02, 2020 08:00 am ET
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the...
Oct 31, 2020 07:15 pm ET
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Sep 29, 2020 01:37 am ET
Spring Bank Class Action: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spring Bank Pharmaceuticals, Inc.; Investors Are Encouraged to Contact the Firm - SBPH
Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) in connection with its merger with F-star Therapeutics Limited. The lawsuit seeks damages and/or equitable relief on behalf of Spring Bank shareholders under the federal securities laws.
Sep 28, 2020 11:30 pm ET
Rigrodsky & Long, P.A. Files Class Action Suit Against Spring Bank Pharmaceuticals, Inc.
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Spring Bank Pharmaceuticals, Inc. (“Spring Bank” or the “Company”) (NASDAQ GS:...
Sep 23, 2020 03:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SBPH, NTN, PTI and GLIBA Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law related to Spring Bank’s agreement to acquire F-star...
Sep 21, 2020 10:00 am ET
MERGER ALERT – SBPH, IMMU, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Sep 17, 2020 02:55 pm ET
MERGER ALERT – SBPH and VRTU: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESWIRE / September 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Sep 09, 2020 01:16 pm ET
Moore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek...
Sep 01, 2020 07:38 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Otelco Inc. (NASDAQ: OTEL), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)
Otelco Inc. (NASDAQ: OTEL) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of OTEL to Oak Hill Capital for $11.75 per share. If you are an OTEL investor, and would like...
Aug 20, 2020 02:03 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Jernigan Capital, Inc. (NYSE: JCAP, JCAP-PB), NTN Buzztime, Inc. (NYSE: NTN), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Sy
Jernigan Capital, Inc. (NYSE: JCAP, JCAP-PB)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of JCAP to an affiliate of NexPoint Advisors, L.P. Under the terms of the agreement,...
Aug 17, 2020 07:00 pm ET
MERGER ALERT - MR, SBPH, and TAT: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Aug 13, 2020 09:00 pm ET
SBPH, CNXM, ONDK, and NETE SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ CM: SBPH) regarding possible breaches of fiduciary duties and other violations of law related to Spring Bank’s agreement to acquire F-star...
Aug 11, 2020 11:33 am ET
MERGER ALERT - SKYS, SBPH, and CNXM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 11, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Aug 10, 2020 04:00 pm ET
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the three and six...
Aug 06, 2020 06:58 pm ET
SPRING BANK PARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Spring Bank Pharmaceuticals, Inc. - SBPH
NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Spring Bank Pharmaceuticals, Inc. (NasdaqGS: SBPH) ("the Company") with F-star Therapeutics, Limited in a stock-for-stock transaction.  KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Aug 05, 2020 01:38 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spring Bank Pharmaceuticals, Inc. - SBPH
NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (Nasdaq: SBPH) relating to its agreement to acquire F-star Therapeutics Limited. Under the terms of the agreement, shareholders of SBPH will own approximately 38.8% of the combined company while F-star holders will own approximately 61.2% of the combined company.
Aug 04, 2020 09:42 am ET
SPRING BANK PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
Rigrodsky & Long, P.A. announces that it is investigating Spring Bank Pharmaceuticals, Inc. (“Spring Bank”) (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law related to Spring Bank’s agreement acquire...
Aug 03, 2020 03:33 pm ET
SPRING BANK ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SBPH and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with F-Star Therapeutics, Limited.
Aug 03, 2020 11:45 am ET
MERGER ALERT - INWK, SBPH, and NBL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 3, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Jul 31, 2020 08:53 pm ET
Spring Bank Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Spring Bank Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The
NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with Spring Bank's proposed merger with F-star Therapeutics, Limited.
Jul 31, 2020 01:35 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spring Bank Pharmaceuticals, Inc.
Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals stockholders will own approximately 38.8% of the combined company. The transaction is expected to close in late 2020.
Jul 29, 2020 04:27 pm ET
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, and F-star Therapeutics, Limited (“F-star”), a privately-held...
Jun 03, 2020 08:00 am ET
Spring Bank Advances IV SB 11285 Clinical Program
Clinical Poster for IV SB 11285 Phase 1a/1b trial presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting HOPKINTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a...
May 26, 2020 04:30 pm ET
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be...
May 20, 2020 07:00 am ET
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will be...
May 07, 2020 04:30 pm ET
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the first quarter...
Apr 02, 2020 08:00 am ET
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today provided an update on the company’s business operations in response to and as a...
Feb 25, 2020 08:00 am ET
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the...
Feb 14, 2020 09:37 am ET
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth quarter...
Jan 29, 2020 08:30 am ET
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has discontinued...
Dec 26, 2019 06:00 am ET
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that the company has...
Dec 09, 2019 08:00 am ET
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV)...
Nov 20, 2019 09:00 am ET
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated...
Nov 12, 2019 08:00 am ET
Spring Bank Announces Investor Conference Presentations for the Remainder of 2019
Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief...
Nov 07, 2019 04:30 pm ET
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for...
Oct 17, 2019 08:00 am ET
Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced interim top-line results at...
Sep 23, 2019 08:00 am ET
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll,...
Sep 17, 2019 08:00 am ET
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr. Thomas Hayman, MD,...
Sep 04, 2019 08:00 am ET
Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into a...
Aug 06, 2019 08:00 am ET
Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into a...
Jul 31, 2019 04:30 pm ET
Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for...
Jul 29, 2019 08:00 am ET
Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that its Investigational New Drug...
Jul 23, 2019 08:15 am ET
Spring Bank Announces Dosing of Inarigivir 400mg In Multiple HBV Studies
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced dosing of patients with...
Jul 18, 2019 11:00 am ET
Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entered into a...
Jul 10, 2019 04:00 pm ET
Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein, M.D.,...
Jul 01, 2019 08:00 am ET
Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has submitted an...
Jun 27, 2019 08:30 am ET
Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present for...
Jun 06, 2019 08:00 am ET
Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it would present promising...
May 28, 2019 08:00 am ET
Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll,...
Apr 29, 2019 07:00 am ET
Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for...
Apr 12, 2019 06:00 am ET
Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced at The International Liver...
Apr 10, 2019 04:01 pm ET
Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a conference...
Mar 28, 2019 08:00 am ET
Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the acceptance of a late...
Mar 14, 2019 08:00 am ET
Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Nezam Afdhal, M.D.,...
Mar 11, 2019 06:30 am ET
Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for...
Mar 04, 2019 04:01 pm ET
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host a...
Feb 19, 2019 04:38 pm ET
Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced the appointment of Atif...
Dec 18, 2018 04:15 pm ET
Spring Bank Pharmaceuticals Appoints Scott Smith as Chairman of the Board
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it has appointed successful...
Dec 06, 2018 07:00 am ET
Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, will host a research and development day...
Nov 29, 2018 08:00 am ET
Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced additional pre-clinical...
Nov 09, 2018 08:00 am ET
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that principal...
Nov 05, 2018 08:00 am ET
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present at two...
Nov 01, 2018 08:00 am ET
Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will present data from...
Oct 29, 2018 11:00 am ET
Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a Research &...
Oct 25, 2018 04:30 pm ET
Spring Bank Pharmaceuticals Reports Third Quarter Financial Results
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its 2018 third quarter...
Oct 03, 2018 05:02 pm ET
Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will present inarigivir...
Sep 17, 2018 08:00 am ET
Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll,...
Aug 16, 2018 08:00 am ET
Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has added Scott...
Aug 08, 2018 09:33 pm ET
Spring Bank Announces Pricing of Public Offering of Common Stock
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $12.50 per share, for expected gross proceeds of $37.5 million...
Aug 08, 2018 04:01 pm ET
Spring Bank Announces Proposed Public Offering of Common Stock
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be...
Aug 02, 2018 06:00 am ET
Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced positive results from the third cohort (inarigivir 100mg) of Part A of the ongoing Phase 2 ACHIEVE trial.  Spring Bank also announced the expansion of the Phase 2 clinical trial being...
Aug 01, 2018 04:01 pm ET
Spring Bank Pharmaceuticals Reports Second Quarter Financial Results
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its 2018 second quarter...
May 29, 2018 08:30 am ET
Spring Bank to Present at Jefferies 2018 Global Healthcare Conference
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll,...
Apr 27, 2018 08:00 am ET
Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences
Apr 10, 2018 08:30 am ET
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations
Mar 14, 2018 08:00 am ET
Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg
Mar 09, 2018 02:19 pm ET
Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference
HOPKINTON, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman,...
Mar 05, 2018 04:01 pm ET
Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
Spring Bank strengthens Board of Directors with the addition of aprominent biopharma R&D veteran
Feb 21, 2018 06:40 am ET
Spring Bank Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 8:30 AM Eastern Time.
Feb 20, 2018 04:30 pm ET
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic
Jan 09, 2018 08:30 am ET
Spring Bank Strengthens Management Team to Enhance Operations
Appoints Kevin Leach, Ph.D., as Vice President, Nonclinical & Translational Research
Nov 15, 2017 04:30 pm ET
Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints
Nov 07, 2017 08:00 am ET
Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman,...
Jul 31, 2017 04:15 pm ET
Jul 10, 2017 08:30 am ET
Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
HOPKINTON, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases, and certain cancers today announced a second clinical trial collaboration with Gilead Sciences, Inc. for a clinical study examining the use of Spring Bank’s oral selective immunomodulator, SB 9200, co-administered with Gilead’s Vemlidy® (tenofovir alafenamide) in chronic Hepatitis B (HBV) patients....
Jun 07, 2017 07:00 am ET
Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
HOPKINTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was published at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 – 6th in Chicago, IL.  The Spring Bank abstract was titled “Preclinical Studies of SB 11285, a Novel STING (STimulator of INterferon Genes) Agonist for Immuno-Oncology.” The abstract includes results from the efficacy studies of SB 11285 in the syngeneic mouse models of A20 lymphoma and CT26 colon cancer, which both show...
May 23, 2017 04:00 pm ET
Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
SB 9200 Shows Favorable Safety Profile and Significant Antiviral Activity Against HBV DNA and HBsAg with Initial Low Dose Monotherapy of 25mg...
May 22, 2017 04:00 pm ET
Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial
HOPKINTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that the company’s management team plans to host a conference call on Wednesday, May 24, 2017, at 8:00 a.m. ET, to discuss top-line results from the initial 25mg monotherapy dosing cohort of the Phase 2a segment of its ACHIEVE trial, a global, placebo-controlled, sequential-cohort, double-blind Phase 2 clinical trial for chronic Hepa...
Feb 15, 2017 08:00 am ET
Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results
HOPKINTON, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today provided an update on recent corporate and clinical developments and reported financial results for the fourth quarter and full year ended December 31, 2016....
Oct 31, 2016 07:00 am ET
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2016 Financial Results
HOPKINTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced third quarter 2016 financial results and provided an update on recent corporate and clinical developments....
Oct 20, 2016 07:30 am ET
Spring Bank Pharmaceuticals Presents Data on STING Agonist SB 11285 at the AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases today announced the presentation of scientific data relating to its novel, proprietary STING (STimulator of INterferon Genes) agonist compound, SB 11285, at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy taking place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, ...
Oct 13, 2016 07:30 am ET
Spring Bank Pharmaceuticals to Present at Dawson James Securities 2016 Stock Growth Conference
HOPKINTON, Mass., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals will present at the Dawson James Securities 2016 Stock Growth Conference on Thursday, October 20th at 10:45 AM Eastern Time at the Wyndham Grand Hotel in Jupiter, Florida. For more information on the conference or for investors to register, please go to DJS Conf...
Sep 06, 2016 04:05 pm ET
Spring Bank Pharmaceuticals Abstracts on STING Agonist SB 11285 Accepted for Poster Presentations at AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced that two abstracts related to SB 11285, the Company’s novel, proprietary STING agonist compound for immuno-oncology, have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy taking place on October 20-23, 2016 at the Boston...
Aug 22, 2016 05:00 pm ET
Spring Bank Pharmaceuticals, Inc. to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13th, 2016
HOPKINTON, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced it will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 13th at 11:40 am ET. Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals, will provide an overview of the Company's business during the live presentation and Jon Freve, CFO, will also be in attendance....
Aug 02, 2016 10:00 am ET
Aug 01, 2016 05:14 pm ET
Spring Bank Pharmaceuticals Announces Second Quarter 2016 Financial Results and Recent Highlights
HOPKINTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced second quarter 2016 financial results and provided an update on recent corporate and clinical developments....
Jul 28, 2016 04:05 pm ET
Spring Bank Pharmaceuticals Appoints Dr. Todd C. Brady to its Board of Directors
MILFORD, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and certain inflammatory diseases, today announced the appointment of Dr. Todd C. Brady to the Company’s Board of Directors, effective July 28, 2016. Dr. Brady currently serves as Chief Executive Officer, President and Director of Aldeyra Therapeutics (Nasdaq:ALDX), a developer of drugs for the treatment of inflammation and inborn errors of metabolism....
Jun 27, 2016 08:00 am ET
Spring Bank Pharmaceuticals Added to Russell Microcap® Index
HOPKINTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and cancer, announced that it was added to the Russell Microcap® Index when the Russell Investment Group reconstituted its family of U.S. indexes effective today, June 27, 2016....
Jun 22, 2016 08:00 am ET
Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B (HBV) 
HOPKINTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and cancer, today announced that it has begun dosing the first cohort of patients in the ACHIEVE global Phase 2 clinical program evaluating SB 9200 in immuno-active, treatment-naïve HBV patients without cirrhosis. SB 9200 is the Company’s novel small molecule nucleic acid hybrid (SMNH) compound being developed as both monotherapy and combination therapy for the...
May 25, 2016 08:00 am ET
Spring Bank Pharmaceuticals to Present at Upcoming Investor Conferences
MILFORD, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that the Company will present at the following upcoming investor conferences:...
May 11, 2016 02:17 pm ET
Spring Bank Pharmaceuticals Announces Closing of Initial Public Offering
MILFORD, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the closing of its initial public offering of 920,000 shares of common stock at a public offering price of $12.00 per share, resulting in gross proceeds of approximately $11 million, before underwriting discounts and commissions and offering-related expenses. All of the shares in the offering were sold by Spring Bank.  In addition, Spring Bank has granted the underwri...
May 06, 2016 11:49 am ET
UPDATE -- Spring Bank Pharmaceuticals Announces Pricing of Initial Public Offering
MILFORD, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the pricing of its initial public offering of 920,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Spring Bank. In addition, Spring Bank has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting...
May 06, 2016 08:00 am ET
Spring Bank Pharmaceuticals Announces Pricing of Initial Public Offering
MILFORD, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the pricing of its initial public offering of 920,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Spring Bank. In addition, Spring Bank has granted the underwriters a 30-day option to purchase from the company, at the public offering price, less underwriting...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.